Bioabsorbable and biocompatible stents. Is a new revolution coming?

Minerva Cardioangiologica

Volumn 56, Issue 5, 2008, Pages 483-491

  Rogacka, R ^a   Chieffo, A ^b   Latib, A ^b   Colombo, A ^b  

^a DESIO HOSPITAL   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Angioplasty, balloon; Coronary artery disease; Drug eluting stents

Indexed keywords

BIOLIMUS A9; BIOMATERIAL; MAGNESIUM; PACLITAXEL; POLYGLACTIN; POLYLACTIC ACID; POLYMER; RAPAMYCIN; RAPAMYCIN DERIVATIVE; STAINLESS STEEL; TACROLIMUS; UNCLASSIFIED DRUG;

BIODEGRADABLE IMPLANT; CLINICAL TRIAL; CORONARY STENT; DRUG ELUTING STENT; HUMAN; LATE STENT THROMBOSIS; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; REVIEW; SAFETY; THROMBOSIS;

ABSORBABLE IMPLANTS; BIOCOMPATIBLE MATERIALS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HUMANS; PROSTHESIS DESIGN;

EID: 55749105135     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9.
2. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78.
3. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21.
4. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. Jama 2005;293:2126-30.
5. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-92.
6. Stabile E, Cheneau E. Kinnaird T, Suddath WO, Weissman NJ, Torguson R et al. Late thrombosis in cypher stents after the discontinuation of antiplatelet therapy. Cardiovasc Radiat Med 2004;5:173-6.
7. Airoldi F, Colombo A, Morici N, Latib A, Cosgrove J, Buellesfeld L et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-54.
8. Cutlip DE. Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1907-71.
9. Kuchulakanti PK, Chu WW, Torguson R. Ohlmann P, Rha SW, Clavijo LC et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006;113:1108-13.
10. Okabe T, Mintz GS, Buch AN, Roy P, Hong YJ, Smith KA et al. Intravascular ultrasound parameters associated with stent thrombosis after drug-eluting stent deployment. Am J Cardiol 2007;100:615-20.
11. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:2001-9.
12. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during longterm follow-up. Am J Cardiol 2006;98:352-6.
13. Farb A, Boam AB. Stem thrombosis redux - the FDA perspective. N Engl J Med 2007;356:984-7.
14. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MD et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-41.
15. Joner M, Finn AV, Farb A, Mont EK, Kolodgie F, Ladich E et al Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
16. Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation 2007;116:910-6.
17. Kotani J, Awata M, Nanto S, Uematsu M, Osjima F. Minamiguhi H et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006;47:2108-11.
18. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW. Holmes DR Jr et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-7.
19. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5.
20. Han Y. Multicenter Registry of Excel Biodegradable Polymer Drug Eluting Stent (CREATE), 9-months angiographie and 12-months clinical results. American College of Cardiology 2008 Scientific Sessions/i2 Summit-SCAI Annual Meeting; March 31, 2008; Chicago. IL. Late-breaking clinical trials 3 2008.
21. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
22. Lee CH, Lim J, Low A, Zhang XL, Kyaing TT, Chan MY et al. Sirolimus-eluting, bioabsorbable polymer-coated constant stent (Cura) in acute ST-elevation myocardial infarction: a clinical and angiographic study (CURAMI Registry). J Invasive Cardiol 2007;19:182-5.
23. Tin Hay E, Hou XM, Lim J, Low A. Teo SG, Tan HC et al. A novel drug-eluting stent using bioabsorbable polymer technology: Two-year follow-up of the CURAMI registry. Int J Cardiol 2007 Oct 15. [Epub ahead of print].
24. Lemos PA. Percutaneous Intervention with Biodegradable Polymer-Based Paclitaxel Eluting, Sirolimus Eluting, or Bare Metal Stents for the Treatment of de novo Coronary Lesions (PAINT) Study. Scientific Sessions, Late Breaking Trials, Euro PCR, Barcellona May 13-16, 2008.
25. Aoki J, Abizaid AC, Serruys PW, Ong AT, Boerma E, Sousa JE et al. Evaluation of four-year coronary artery-response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol 2005;46:1670-6.
26. Serruys PW, Sianos G, Abizaid A, aoki J, den Heijer P, Bonnier H et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 2005;46:253-60.
27. Chevalier B. NOBORI 1-long term results: two years phase 1, one year phase 2. Scientific Session, Late Breaking Trials, Euro PCR, Barcellona May 13-16, 2008.
28. Chevalier B, Serruys PW, Silber S, Garcia E, Suryapranata H, Hauptmann KE. Randomised comparison of Nobori TM, biolimus A9-eluting coronary stent with Taxus, paclitaxel-eluting coronary stent in patients with stenosis in ntive coronary arteries: the Nobori 1 trial. EuroIntervention 2007;2:426-34.
29. Windecker S, Simon R, Lins M, Klauss V, Eberli FR, Roffi M et al. Randomized comparison of a titaniumnitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation 2005;111:2617-22.
30. Rajtar A, Kaluza GL, Yang Q, Hakimi D, Liu D, Tsui M et al. Hydroxyapatite-coated cardiovascular stents. EuroIntervention 2006;2:113-5.
31. Kollum M, Farb A, Schreiber R, Terfera K, Arab A, Geist A. Particle debris from a nanoporus stent coating obscures potential antiproliferative effects of tacrolimuseluting stents in a porcine model of restenosis. Catheter Cardiovasc Interv 2005:85-90.
32. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S et al. Initial and 6-month results of biodegradable poly-1-lactic acid coronary stents in humans. Circulation 2000;102:399-404.
33. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907.
34. Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimuseluting coronary stent. Catheter Cardiovasc Interv 2007;69:128-31.
35. Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimuseluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 2007;70:515-23.
36. Serruys PW, Ong ATL, Piek JJ. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. Eurolntervention 2005;1:58-65.
37. Serruys PW, Ruygrok P, Neuzner J. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2006;2:286-94.
38. Schultz RK. REVA Medical Inc. Bioabsorbable Stent. Scientific Session, Late Breaking Trials, CRT, Washington DC, Sept 16-19, 2007.
39. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007;369:1869-75.